Evaluation of the effect of CYP2D6*3, *4,*10, and *17 polymorphisms on the pharmacokinetic of tamoxifen and its metabolites in patients with hormone-positive breast cancer.

Abstract excerpt

BACKGROUND AND OBJECTIVE: A high rate of interindividual variability in response to tamoxifen (TAM) in breast cancer patients with CYP2D6 polymorphism has been reported, which affects the patient's therapeutic outcome. The objective of this study was to investigate the pharmacogenomics of CYP2D6 genotyping in Iranian patients with breast cancer treated with adjuvant TAM. METHODS: A peripheral blood sample was...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antineoplastic Agents, Hormonal
• Share to Breast Neoplasms